NCT03840174View on ClinicalTrials.gov

Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

November 7, 2019

Study Completion Date

November 7, 2019

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

V160

V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)

OTHER

Placebo

Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection

Trial Locations (1)

812-0025

Souseikai PS Clinic ( Site 0001), Fukuoka

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03840174 - Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) | Biotech Hunter | Biotech Hunter